ZA201701467B - Methods and biocompatible compositions to achieve sustained drug release in the eye - Google Patents

Methods and biocompatible compositions to achieve sustained drug release in the eye

Info

Publication number
ZA201701467B
ZA201701467B ZA2017/01467A ZA201701467A ZA201701467B ZA 201701467 B ZA201701467 B ZA 201701467B ZA 2017/01467 A ZA2017/01467 A ZA 2017/01467A ZA 201701467 A ZA201701467 A ZA 201701467A ZA 201701467 B ZA201701467 B ZA 201701467B
Authority
ZA
South Africa
Prior art keywords
eye
methods
drug release
sustained drug
achieve sustained
Prior art date
Application number
ZA2017/01467A
Other languages
English (en)
Inventor
Brendan Hackett
Kevin L Ward
Koushik Barman
Moli Liu
Shikha P Barman
Original Assignee
Integral Biosystems Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Biosystems Llc filed Critical Integral Biosystems Llc
Publication of ZA201701467B publication Critical patent/ZA201701467B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting in contact-lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials For Medical Uses (AREA)
ZA2017/01467A 2014-09-06 2017-02-27 Methods and biocompatible compositions to achieve sustained drug release in the eye ZA201701467B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462046918P 2014-09-06 2014-09-06
PCT/US2015/048795 WO2016037169A1 (en) 2014-09-06 2015-09-08 Methods and biocompatible compositions to achieve sustained drug release in the eye

Publications (1)

Publication Number Publication Date
ZA201701467B true ZA201701467B (en) 2018-04-25

Family

ID=55440434

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2017/01467A ZA201701467B (en) 2014-09-06 2017-02-27 Methods and biocompatible compositions to achieve sustained drug release in the eye
ZA2017/05792A ZA201705792B (en) 2014-09-06 2017-08-25 Methods and biocompatible compositions to achieve sustained drug release in the eye

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2017/05792A ZA201705792B (en) 2014-09-06 2017-08-25 Methods and biocompatible compositions to achieve sustained drug release in the eye

Country Status (12)

Country Link
US (2) US9931306B2 (enExample)
EP (1) EP3188688B1 (enExample)
JP (2) JP7026507B2 (enExample)
KR (1) KR102456032B1 (enExample)
CN (2) CN109481447A (enExample)
AU (2) AU2015311637B2 (enExample)
CA (1) CA2960213C (enExample)
ES (1) ES2900025T3 (enExample)
MY (1) MY178327A (enExample)
SG (1) SG11201701714RA (enExample)
WO (1) WO2016037169A1 (enExample)
ZA (2) ZA201701467B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3188688B1 (en) * 2014-09-06 2021-11-03 Integral Biosystems LLC Methods and biocompatible compositions to achieve sustained drug release in the eye
US11458041B2 (en) * 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
ES3030351T3 (en) * 2016-09-30 2025-06-27 Mati Therapeutics Inc Ophthalmic drug sustained release formulation and uses thereof
WO2018217662A1 (en) * 2017-05-22 2018-11-29 California Institute Of Technology Small molecule transport device with anti-condensation filler for drug delivery or waste removal
US20200206137A1 (en) * 2017-07-17 2020-07-02 Wolfcreek Biotech Pte Ltd Microparticle formulations for delivery of active agents
EP3758639A4 (en) 2018-03-01 2021-12-15 Bar Ilan University SYSTEM, METHOD AND COMPOSITION OF MATERIAL FOR USE IN CORRECTION OF EYE PROBLEMS
MX2020013230A (es) * 2018-06-05 2021-02-22 Corneat Vision Ltd Un parche de injerto oftalmico sintetico.
CN109853054A (zh) * 2019-02-27 2019-06-07 上海交通大学医学院附属第九人民医院 一种同轴静电纺丝三维打印生物支架的装置及搭建方法
EP3701974B1 (en) * 2019-02-28 2024-08-28 Agency for Science, Technology and Research A material suitable for use as a vitreous substitute and related methods
AU2020232314C1 (en) * 2019-03-05 2024-03-28 Alcon Inc. Pharmaceutical compositions for treating ocular diseases or disorders
AU2020251710A1 (en) * 2019-04-02 2021-11-25 Cytomatrix Limited A composition for the delivery of biologically active agents and uses thereof
TWI826685B (zh) 2019-05-02 2023-12-21 瑞士商愛爾康公司 可溶解聚合物眼睛插入物及其使用方法
BR112022007332A2 (pt) 2019-10-24 2022-07-05 E Labombard Denis Dispositivo ocular, métodos, composição, caixa para conter e dispensar um dispositivo ocular e kit
AU2020400389B2 (en) * 2019-12-10 2024-02-15 Alcon Inc. Dissolvable polymeric eye inserts with a biodegradable polymer
CA3177005A1 (en) 2020-04-27 2021-11-04 Michael Goldstein Methods of treating allergic conjunctivitis
KR102467288B1 (ko) * 2020-06-09 2022-11-17 동국대학교 산학협력단 결막 접촉용 약물 전달기
EP3928805A1 (en) * 2020-06-26 2021-12-29 Royal College of Surgeons in Ireland A device for use in the delivery of an active agent
JP2023550632A (ja) * 2020-11-23 2023-12-04 サイト サイエンシーズ， インコーポレイテッド 眼の症状を処置するための製剤および方法
EP4346790A4 (en) * 2021-05-26 2025-04-16 The Texas A&M University System Biodegradable mucoadhesive pharmaceutical formulations and methods thereof
CN114869862A (zh) * 2022-04-24 2022-08-09 温州医科大学附属眼视光医院 一种带引流功能的青光眼手术缓释抗瘢痕膜及制备方法
WO2025050106A1 (en) * 2023-08-31 2025-03-06 University Of Tennessee Research Foundation Sustained release ocular implants
WO2025255203A1 (en) * 2024-06-06 2025-12-11 Ocular Therapeutix, Inc. Compositions and methods for treating ocular diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
US5177168A (en) 1989-10-17 1993-01-05 Polymer Technology Corp. Polymeric compositions useful in oxygen permeable contact lenses
AU700903B2 (en) 1994-10-12 1999-01-14 Focal, Inc. Targeted delivery via biodegradable polymers
US8273366B2 (en) 2002-06-05 2012-09-25 University Of Florida Research Foundation, Incorporated Ophthalmic drug delivery system
CN101180086A (zh) * 2005-04-08 2008-05-14 苏尔莫迪克斯公司 用于经视网膜下递送的持续释放植入物
EP3556319A1 (en) * 2005-05-24 2019-10-23 Inspire M.D Ltd. Stent apparatuses for treatment via body lumens
AU2006348901C1 (en) * 2006-09-28 2013-11-14 Essity Hygiene And Health Aktiebolag Absorbent article, belt structure, manufacturing method for a belt structure and manufacturing method for an absorbent article
WO2008055072A2 (en) * 2006-10-27 2008-05-08 Lpath, Inc. Compositions and methods for treating ocular diseases and conditions
AU2007334248B2 (en) * 2006-12-18 2013-06-27 Alcon Research, Ltd. Devices and methods for ophthalmic drug delivery
US8974814B2 (en) * 2007-11-12 2015-03-10 California Institute Of Technology Layered drug delivery polymer monofilament fibers
US8083347B2 (en) * 2008-04-29 2011-12-27 Ocugenics, LLC Drug delivery system and methods of use
US8361492B2 (en) * 2008-04-29 2013-01-29 Ocugenics, LLC Drug delivery system and methods of use
US20100104654A1 (en) * 2008-10-27 2010-04-29 Allergan, Inc. Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof
US20100291182A1 (en) * 2009-01-21 2010-11-18 Arsenal Medical, Inc. Drug-Loaded Fibers
WO2010093873A2 (en) 2009-02-12 2010-08-19 Incept, Llc Drug delivery through hydrogel plugs
US20100247606A1 (en) * 2009-03-25 2010-09-30 Allergan, Inc. Intraocular sustained release drug delivery systems and methods for treating ocular conditions
WO2010151779A1 (en) * 2009-06-25 2010-12-29 Optonol Ltd. Fiber matrix for maintaining space in soft tissues
EP2525776B1 (en) 2010-01-22 2015-10-28 Allergan, Inc. Intracameral sustained release therapeutic agent implants
US20110229551A1 (en) * 2010-03-17 2011-09-22 Notus Laboratories, Inc. Drug delivery compositions and methods using nanofiber webs
US9028860B2 (en) * 2010-04-28 2015-05-12 Poly-Med, Inc. Partially microcellular, selectively hydrophilic composite construct for ocular drug delivery
US8939948B2 (en) 2010-06-01 2015-01-27 Forsight Vision5, Inc. Ocular insert apparatus and methods
WO2012114138A1 (fr) * 2011-02-21 2012-08-30 Cerebel-Invest Sa Implants biodégradables pour la libération contrôlée sous-conjonctivale d'une molécule active
WO2012149287A1 (en) 2011-04-29 2012-11-01 Allergan, Inc. Solvent cast film sustained release latanoprost implant
CN203089455U (zh) * 2013-02-01 2013-07-31 浙江大学医学院附属第二医院 襻上镶嵌有药物缓释微囊的人工晶状体
EP3188688B1 (en) * 2014-09-06 2021-11-03 Integral Biosystems LLC Methods and biocompatible compositions to achieve sustained drug release in the eye

Also Published As

Publication number Publication date
KR102456032B1 (ko) 2022-10-18
US20180280313A1 (en) 2018-10-04
JP2022001582A (ja) 2022-01-06
MY178327A (en) 2020-10-08
KR20170052582A (ko) 2017-05-12
JP2017526655A (ja) 2017-09-14
AU2015311637A1 (en) 2017-03-23
EP3188688A1 (en) 2017-07-12
CA2960213C (en) 2023-03-28
CN109481447A (zh) 2019-03-19
SG11201701714RA (en) 2017-04-27
ZA201705792B (en) 2018-12-19
NZ729467A (en) 2024-04-26
CN106604695B (zh) 2018-10-23
US10328033B2 (en) 2019-06-25
WO2016037169A1 (en) 2016-03-10
US20170296483A1 (en) 2017-10-19
AU2019250153A1 (en) 2019-10-31
JP7026507B2 (ja) 2022-02-28
ES2900025T3 (es) 2022-03-15
AU2015311637B2 (en) 2019-07-18
EP3188688B1 (en) 2021-11-03
AU2019250153B2 (en) 2021-02-04
US9931306B2 (en) 2018-04-03
EP3188688A4 (en) 2018-07-25
CN106604695A (zh) 2017-04-26
CA2960213A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
ZA201705792B (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
EP3137116A4 (en) Dendrimer compositions and their use in treatment of diseases of the eye
IL252159B (en) Methods and formulations for the treatment of diseases of the blood vessels of the eye
SG10202002593SA (en) Activated bifidobacteria and methods of use thereof
GB2534873B (en) Improvements in and relating to horseshoes
SG11201609490QA (en) Polymer-flavonoid conjugate and uses thereof
IL251120A0 (en) Immunogenic/therapeutic glycoside preparations and their uses
IL251836A0 (en) Compositions and methods of physiological introduction of cannabinoids
SG11201704695WA (en) Ophthalmic composition comprising cyclosporine and trehalose
ZA201703398B (en) Pharmaceutical composition and methods
IL248424B (en) Neuroprotective substances and their uses
EP3145508C0 (en) CLEVIDIPINE NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS THEREOF
PL3129057T3 (pl) Glikolipidy i ich kompozycje farmaceutyczne do stosowania w leczeniu
EP3191119A4 (en) Immunogenic lhrh composition and use thereof in pigs
GB201418809D0 (en) Therapeutic agents and uses thereof
EP3197470A4 (en) Cis-gnetin h and trans-gnetin h as therapeutic agents
GB2517846B (en) Improvements in and relating to loudspeakers
GB2527909B (en) Improvements in and relating to imaging of the eye
HK1235660A1 (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
GB201421006D0 (en) Improvements in and relating to hydrostatic release units
GB201410254D0 (en) Improvements in and relating to kettles
HK1220029B (en) Improvements in and relating to imaging of the eye
GB201415915D0 (en) Improvements in and Relating to ophthalmoscopes
HK1197719A (en) Improvements in and relating to ophthalmoscopes
HK1197719B (en) Improvements in and relating to ophthalmoscopes